Targeting the "rising DAMP" during a Francisella tularensis infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4222-4228

  D'Elia, Riccardo V ^a   Laws, Thomas R ^a   Carter, Alun ^a   Lukaszewski, Roman ^a   Clark, Graeme C ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN POLYCLONAL ANTIBODY; IMMUNOGLOBULIN Y; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; LEVOFLOXACIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL LOAD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; INFLAMMATION; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL; TULAREMIA;

EID: 84882386571     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01885-12     Document Type: Article

References (33)

1. D'Elia R, Jenner DC, Laws TR, Stokes MGM, Jackson MC, Essex-Lopresti AE, Atkins HS. 2011. Inhibition of Francisella tularensis LVS infection of macrophages results in a reduced inflammatory response: evaluation of a therapeutic strategy for intracellular bacteria. FEMS Immunol. Med. Microbiol. 62:348-361.
2. Hall JD, Woolard MD, Gunn BM, Craven RR, Taft-Benz S, Frelinger JA, Kawula TH. 2008. Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112. Infect. Immun. 76:5843-5852.
3. Ellis J, Oyston PCF, Green M, Titball RW. 2002. Tularemia. Clin. Microbiol. Rev. 15:631-646.
4. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, Lillibridge SR, Mcdade JE, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K. 2001. Tularemia as a biological weapon-medical and public health management. JAMA 285:2763-2773.
5. Kortepeter MG, Parker GW. 1999. Potential biological weapons threats. Emerg. Infect. Dis. 5:523-527.
6. McLendon MK, Apicella MA, Allen LAH. 2006. Francisella tularensis: taxonomy, genetics, and immunopathogenesis of a potential agent of biowarfare. Annu. Rev. Microbiol. 60:167-185.
7. Sjostedt A. 2007. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Blackwell Publishing, Oxford, England.
8. Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA. 1991. Live vaccine strain of Francisella tularensis-infection and immunity in mice. Infect. Immun. 59:2922-2928.
9. Oyston PCF. 2009. Francisella tularensis vaccines. Vaccine 27(Suppl 4): D48-D51.
10. Piercy T, Steward J, Lever MS, Brooks TJG. 2005. In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice. J. Antimicrob. Chemother. 56:1069-1073.
11. Russell P, Eley SM, Fulop MJ, Bell DL, Titball RW. 1998. The efficacy of ciprofloxacin and doxycycline against experimental tularaemia. J. Antimicrob. Chemother. 41:461-465.
12. Steward J, Piercy I, Lever MS, Simpson AJH, Brooks TJG. 2006. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. Int. J. Antimicrob. Agents 27:439-443.
13. Klimpel GR, Eaves-Pyles T, Moen ST, Taormina J, Peterson JW, Chopra AK, Niesel DW, Carness P, Haithcoat JL, Kirtley M, Ben Nasr A. 2008. Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. Vaccine 26:6874-6882.
14. Mares CA, Ojeda SS, Morris EG, Li Q, Teale JM. 2008. Initial delay in the immune response to Francisella tularensis is followed by hypercytokinemia characteristic of severe sepsis and correlating with upregulation and release of damage-associated molecular patterns. Infect. Immun. 76: 3001-3010.
15. Sharma J, Mares CA, Li Q., Morris EG, Teale JM. 2011. Features of sepsis caused by pulmonary infection with Francisella tularensis type A strain. Microb. Pathog. 51:39-47.
16. Cowley SC. 2009. Proinflammatory cytokines in pneumonic tularemia: too much too late? J. Leukoc. Biol. 86:469-470.
17. Sharma J, Li Q., Mishra BB, Pena C, Teale JM. 2009. Lethal pulmonary infection with Francisella novicida is associated with severe sepsis. J. Leukoc. Biol. 86:491-504.
18. D'Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. 2013. Targeting the "cytokine storm" for therapeutic benefit. Clin. Vaccine Immunol. 20:319-327.
19. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. 2012. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76:16-32.
20. Stanford MM, McFadden G, Karupiah G, Chaudhri G. 2007. Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol. Cell Biol. 85:93-102.
21. Elkins KL, Cowley SC, Bosio CM. 2007. Innate and adaptive immunity to Francisella. Ann. N. Y. Acad. Sci. 1105:284-324.
22. Conlan JW, Zhao XG, Harris G, Shen H, Bolanowski M, Rietz C, Sjostedt A, Chen WX. 2008. Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis. Mol. Immunol. 45:2962-2969.
23. Bosio CM, Bielefeldt-Ohmann H, Belisle JT. 2007. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J. Immunol. 178:4538-4547.
24. Stern D, Yan SD, Yan SF, Schmidt AM. 2002. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv. Drug Deliv. Rev. 54:1615-1625.
25. Yang H, Wang HC, Czura CJ, Tracey KJ. 2005. The cytokine activity of HMGB1. J. Leukoc. Biol. 78:1-8.
26. Yang H, Czura CJ, Tracey KJ. 2005. HMGB1 as a late mediator and therapeutic target in sepsis. Shock 23:29.
27. Wang HC, Bloom O, Zhang MH, Vishnubhakat JM, Ombrellino M, Che JT, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251.
28. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC. 1995. Efficacy and safety of monoclonal-antibody to human tumor-necrosisfactor-alpha in patients with sepsis syndrome-a randomized, controlled, double-blind, multicenter clinical trial. JAMA 273:934-941.
29. Yang H, Ochani M, Li JH, Qiang XL, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang HC, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101:296-301.
30. Entezari M, Weiss DJ, Sitapara R, Whittaker L, Wargo MJ, Li JH, Wang HC, Yang H, Sharma L, Phan BD, Javdan M, Chavan SS, Miller EJ, Tracey KJ, Mantell LL. 2012. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol. Med. 18:477-485.
31. Anthony LS, Ghadirian E, Nestel FP, Kongshavn PA. 1989. The requirement for gamma interferon in resistance of mice to experimental tularemia. Microb. Pathog. 7:421-428.
32. Leiby DA, Fortier AH, Crawford RM, Schreiber RD, Nacy CA. 1992. In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect. Immun. 60:84-89.
33. Sjöstedt A, North RJ, Conlan JW. 1996. The requirement of tumour necrosis factor-alpha and interferon-gamma for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum. Microbiology 142:1369-1374.